FOXP3 and ovarian cancer: The estimated pooled HR for these two studies suggested that the risk of disease progression was not associated with intraepithelial CD8+/FoxP3+ ratio in ovarian cancer patients (Figure 6A; HR, 0.73; 95%CI, 0.53-1.02; PHR=0.064; I2=0.0%; fixed effects model).